SCHEMBL21626257

SCHEMBL21626257

c1ccc(COC2CCOc3ccnn3C2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 2/20 0.43
CTSB P07858 2/20 0.43
CTSK P43235 2/20 0.43
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
NAAA Q02083 4/20 0.39
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38
CARM1 Q86X55 1/20 0.38
PRMT6 Q96LA8 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
PRMT8 Q9NR22 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
CYP11B2 P19099 1/20 0.37
OPRM1 P35372 2/20 0.36
OPRL1 P41146 2/20 0.36
DPP4 P27487 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21626249 0.79 CARM1 (0.43) CTSLCTSBCTSKALDH1A1LMNA
SCHEMBL28993054 0.75 CTSL (0.47) CTSLCTSBCTSKALDH1A1LMNA
SCHEMBL28993053 0.75 CTSL (0.47) CTSLCTSBCTSKALDH1A1LMNA
SCHEMBL23762905 0.71 CTSL (0.34) CTSLCTSBCTSKNAAACYP11B2
SCHEMBL31248144 0.70 OPRM1 (0.51) CTSLCTSBCTSKNAAATMEM97
SCHEMBL23674500 0.69 LMNA (0.51) CTSLCTSBCTSKLMNANAAA
SCHEMBL19041070 0.68 SIGMAR1 (0.42) CTSLCTSBCTSKALDH1A1TMEM97
SCHEMBL664313 0.68 SIGMAR1 (0.45) CTSLCTSBCTSKALDH1A1TMEM97
SCHEMBL11244939 0.67 CTSL (0.46) CTSLCTSBCTSKNAAATMEM97
SCHEMBL28072324 0.67 CTSL (0.46) CTSLCTSBCTSKNAAATMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115618-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2025-04-10 US disclosed
US-12234245-B2 Sulfonimidamide compounds as inhibitors of interleukin-1 activity GENENTECH, INC. (US) 2025-02-25 US disclosed
US-20210253596-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2021-08-19 US disclosed
US-20210253596-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2021-08-19 US disclosed
EP-3823974-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY F. Hoffmann-La Roche AG (CH) 2021-05-26 EP disclosed
WO-2020018975-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2020-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115618-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY IL1A, IL18, IL1B CTSL 548/4885CTSB 518/4885CTSK 1188/4885
US-20210253596-A1 SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY IL1A, IL18, IL1B CTSL 548/4885CTSB 518/4885CTSK 1188/4885
US-12234245-B2 Sulfonimidamide compounds as inhibitors of interleukin-1 activity IL1A, IL18, IL1B CTSL 548/4885CTSB 518/4885CTSK 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.